April 10, 2026

A mouse model for Dry Eye Disease

A mouse model for Dry Eye Disease

Experimentica utilizes a validated mouse model of dry eye disease. Dry eye disease-like pathology is induced using transdermal scopolamine patches in combination with desiccating environmental stress. The induced pathology is characterized using corneal fluorescein staining, tear volume measurements, and histology for lacrimal gland infiltration, goblet cell loss, and corneal abnormalities.

Dry eye disease, also referred to as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome, is a multifactorial ocular surface disease characterized by ocular discomfort, irritation, and visual disturbance. It ranks among the most frequently encountered ocular morbidities, with more than 25% of patients attending ophthalmic clinics reporting these symptoms (Dana et al. 2019).

The global prevalence of dry eye disease is estimated to range from 7% to 34%, depending on diagnostic criteria and the population surveyed (Deo and Nagrale 2024). The steep rise in annual dry eye disease incidence and prevalence over the past decade has recently been estimated (Zhang et al. 2024).

In 2002, Dursun and colleagues published a mouse model of dry eye disease by combining application of transdermal scopolamine patches together with a desiccating environmental stress (Dursun et al. 2002). At Experimentica, we use corneal fluorescein staining (CFS) to confirm successful model induction.

Figure 1. Corneal fluorescein staining of damaged epithelial cell layer.

CFS is scored using the modified Oxford score method by assigning scores from 0 (healthy corneal epithelial cell layer with no observable fluorescein staining) to 4 (severe corneal epithelial cell damage with widespread confluent staining of the cornea.

Figure 2. Corneal fluorescein score at Day 21 of the study follow-up in naïve, untreated and PBS-treated eyes.

In addition, the evaluation of dry eye disease-like pathology can be performed with tear volume measurements and histological assessment of immune cell infiltration in lacrimal glands, quantification of goblet cells in the conjunctiva or corneal thickness and the number of corneal epithelial layers.

Figure 3. H&E staining of lacrimal gland, PAS staining of Goblet cells, and H&E staining of cornea.

Contact us for more information or schedule the meeting with our experts!

Contact usLearn more about our Dry Eye Disease model

References

Our latest News

discover more
Why pain persists long after injuries have healed

Why pain persists long after injuries have healed

Prof. Dr. Rohini Kuner of the Heidelberg Faculty of Medicine at Heidelberg University awarded the 2026 Jung Prize for Medicine Chronic pain is among the most common and burdensome health conditions worldwide. But which processes in the nervous system cause pain to be “learned” and thus persist long term? And how can insights into the […]

New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

New HI-STEM Publication: A kinetics-based model of haematopoiesisreveals extrinsic regulation of skewed lineageoutput from stem cells

Rodríguez-Correa, E., Grünschläger, F., Nizharadze, T. et al. A kinetics-based model of haematopoiesis reveals extrinsic regulation of skewed lineage output from stem cells. Nat Cell Biol (2026). https://doi.org/10.1038/s41556-026-01958-0 https://www.nature.com/articles/s41556-026-01958-0 Abstract Haematopoietic stem cells (HSCs) display extensive molecular and functional heterogeneity. However, a cohesive model that explains the relationship and biological relevance of these diverse HSC states remains elusive. Here, […]

Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Heidelberg-based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp